Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FluINsure intranasal vaccine: IDBE began a double-blind, placebo-controlled Canadian Phase II trial of FluINsure intranasal vaccine in 90-110 volunteers to prev

ID Biomedical Corp. (IDBE; TSE:IDB), Vancouver,

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE